Oakland, CA, United States of America

Ryan McGuinness


Average Co-Inventor Count = 4.2

ph-index = 4

Forward Citations = 74(Granted Patents)


Location History:

  • Half Moon Bay, CA (US) (2004)
  • Oakland, CA (US) (2004 - 2010)

Company Filing History:


Years Active: 2004-2010

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Ryan McGuinness: Innovator in Gene Therapy

Introduction

Ryan McGuinness is a prominent inventor based in Oakland, CA (US). He has made significant contributions to the field of gene therapy, holding a total of 5 patents. His work focuses on developing advanced methods for transgene delivery, particularly in the treatment of hemophilia.

Latest Patents

Among his latest patents are innovations related to lentiviral vectors featuring liver-specific transcriptional enhancers. These patents disclose recombinant lentiviruses and transfer vectors for transgene delivery, as well as methods for gene therapy using such vectors. The invention provides a third-generation lentiviral packaging system and a set of vectors for producing recombinant lentiviruses. Additionally, it includes novel tissue-specific enhancer and promoter elements that optimize liver-specific transgene delivery. The transgene is preferably a blood clotting factor, such as human factor IX (hFIX) or human factor VIII (hFVIII), which can be utilized for the treatment of hemophilia.

Career Highlights

Ryan has worked with notable companies in the biotechnology sector, including Cell Genesys, Inc. and Gbp IP, LLC. His experience in these organizations has contributed to his expertise in gene therapy and transgene delivery systems.

Collaborations

Throughout his career, Ryan has collaborated with esteemed colleagues, including Thomas L. Dull and James G. McArthur. These partnerships have further enhanced his research and development efforts in the field.

Conclusion

Ryan McGuinness is a key figure in the advancement of gene therapy, with a focus on innovative solutions for hemophilia treatment. His contributions through patents and collaborations continue to impact the biotechnology landscape.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…